These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 27796734)

  • 41. Alpha Internexin: A Surrogate Marker for 1p/19q Codeletion and Prognostic Marker in Anaplastic (WHO grade III) Gliomas.
    Rajmohan KS; Sugur HS; Shwetha SD; Pandey P; Arivazhagan A; Santosh V
    Neurol India; 2020; 68(4):832-837. PubMed ID: 32859823
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas.
    Cryan JB; Haidar S; Ramkissoon LA; Bi WL; Knoff DS; Schultz N; Abedalthagafi M; Brown L; Wen PY; Reardon DA; Dunn IF; Folkerth RD; Santagata S; Lindeman NI; Ligon AH; Beroukhim R; Hornick JL; Alexander BM; Ligon KL; Ramkissoon SH
    Oncotarget; 2014 Sep; 5(18):8083-92. PubMed ID: 25257301
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fluorescence in situ hybridization for 1p, 19q status in a cohort of glial neoplasms.
    Singh VY; Chacko G; Chacko AG; Rajshekhar V
    Neurol India; 2014; 62(1):32-6. PubMed ID: 24608451
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China.
    Li S; Yan C; Huang L; Qiu X; Wang Z; Jiang T
    Neuro Oncol; 2012 Jan; 14(1):109-16. PubMed ID: 22039037
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status.
    Delfanti RL; Piccioni DE; Handwerker J; Bahrami N; Krishnan A; Karunamuni R; Hattangadi-Gluth JA; Seibert TM; Srikant A; Jones KA; Snyder VS; Dale AM; White NS; McDonald CR; Farid N
    J Neurooncol; 2017 Dec; 135(3):601-609. PubMed ID: 28871469
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunohistochemistry on IDH 1/2, ATRX, p53 and Ki-67 substitute molecular genetic testing and predict patient prognosis in grade III adult diffuse gliomas.
    Takano S; Ishikawa E; Sakamoto N; Matsuda M; Akutsu H; Noguchi M; Kato Y; Yamamoto T; Matsumura A
    Brain Tumor Pathol; 2016 Apr; 33(2):107-16. PubMed ID: 26968173
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ATRX loss in glioneuronal tumors with neuropil-like islands indicates similarity to diffuse astrocytic tumors.
    Kakkar A; Nambirajan A; Kaur K; Kumar A; Mallick S; Suri V; Sarkar C; Kale SS; Garg A; Sharma MC
    J Neurooncol; 2016 Oct; 130(1):63-68. PubMed ID: 27469217
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biphasic IDH1 phenotype in a diffusely infiltrating glioma: implications for pathogenesis, treatment and prognosis.
    Odia Y; Varma H; Tsankova NM
    Clin Neuropathol; 2015; 34(5):282-7. PubMed ID: 25907263
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Correlation of 1p-19q-defects in human gliomas with the light microscopic appearance of oligodendroglioma.
    McLendon RE; Rasheed A; Wiltshire R; Herndon J
    Mod Pathol; 2004 May; 17(5):604-5. PubMed ID: 15105803
    [No Abstract]   [Full Text] [Related]  

  • 50. Analysis of isocitrate dehydrogenase 1 mutation in 97 patients with glioma.
    Zhou YX; Wang JX; Feng M; Sun CM; Sun T; Chen GL; Du ZW
    J Mol Neurosci; 2012 Jul; 47(3):442-7. PubMed ID: 22113362
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas.
    Jiang H; Ren X; Cui X; Wang J; Jia W; Zhou Z; Lin S
    Neuro Oncol; 2013 Jun; 15(6):775-82. PubMed ID: 23486687
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunohistochemical ATRX expression is not a surrogate for 1p19q codeletion.
    Yamamichi A; Ohka F; Aoki K; Suzuki H; Kato A; Hirano M; Motomura K; Tanahashi K; Chalise L; Maeda S; Wakabayashi T; Kato Y; Natsume A
    Brain Tumor Pathol; 2018 Apr; 35(2):106-113. PubMed ID: 29550880
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Application of ATRX in diagnosis and prognostic evaluation of glioma].
    Li Z; Piao YS; Zhang LY; Wang LM; Wang DD; Fu YJ; Cai YN; Lu DH
    Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):690-694. PubMed ID: 29050070
    [No Abstract]   [Full Text] [Related]  

  • 54. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
    Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
    Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology.
    Capper D; Reuss D; Schittenhelm J; Hartmann C; Bremer J; Sahm F; Harter PN; Jeibmann A; von Deimling A
    Acta Neuropathol; 2011 Feb; 121(2):241-52. PubMed ID: 21069360
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
    Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J
    World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Correlation of chromosomes 1p and 19q status and expressions of O6-methylguanine DNA methyltransferase (MGMT), p53 and Ki-67 in diffuse gliomas of World Health Organization (WHO) grades II and III: a clinicopathological study.
    Huang L; Jiang T; Yuan F; Li GL; Cui Y; Liu EZ; Wang ZC
    Neuropathol Appl Neurobiol; 2009 Aug; 35(4):367-379. PubMed ID: 19019173
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 1p/19q co-deletion status is associated with distinct tumor-associated macrophage infiltration in IDH mutated lower-grade gliomas.
    Zhang Y; Xie Y; He L; Tang J; He Q; Cao Q; Cui L; Guo W; Hua K; Dimberg A; Wang L; Zhang L
    Cell Oncol (Dordr); 2021 Feb; 44(1):193-204. PubMed ID: 32915415
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The 2016 revision of the WHO Classification of Central Nervous System Tumours: retrospective application to a cohort of diffuse gliomas.
    Rogers TW; Toor G; Drummond K; Love C; Field K; Asher R; Tsui A; Buckland M; Gonzales M
    J Neurooncol; 2018 Mar; 137(1):181-189. PubMed ID: 29218432
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical and histological characteristics of recurrent oligodendroglial tumors: comparison between primary and recurrent tumors in 18 cases.
    Kanamori M; Kumabe T; Shibahara I; Saito R; Yamashita Y; Sonoda Y; Suzuki H; Watanabe M; Tominaga T
    Brain Tumor Pathol; 2013 Jul; 30(3):151-9. PubMed ID: 23053495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.